Integra LifeSciences (NASDAQ:IART) Rating Reiterated by 22nd Century Group

22nd Century Group reiterated their downgrade rating on shares of Integra LifeSciences (NASDAQ:IART – Get Rating) in a research note released on Tuesday morning, Benzinga reports.

IART has been the topic of a number of other reports. JMP Securities reduced their target price on shares of Integra LifeSciences from $75.00 to $65.00 in a report on Thursday, April 27th. StockNews.com started coverage on shares of Integra LifeSciences in a report on Thursday, May 18th. They set a buy rating on the stock. TheStreet lowered shares of Integra LifeSciences from a b- rating to a c+ rating in a report on Monday. Truist Financial reduced their target price on shares of Integra LifeSciences from $58.00 to $54.00 in a report on Thursday, May 18th. Finally, Citigroup lowered shares of Integra LifeSciences from a neutral rating to a sell rating and reduced their price objective for the company from $59.00 to $39.00 in a report on Tuesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences has an average rating of Hold and a consensus price target of $51.14.

Integra LifeSciences Trading Down 0.6 %

Shares of NASDAQ:IART traded down $0.23 during mid-day trading on Tuesday, reaching $38.25. 275,373 shares of the company were exchanged, compared to its average volume of 571,940. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.65 and a quick ratio of 2.40. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of 18.57, a P/E/G ratio of 1.21 and a beta of 1.15. The firm’s 50-day simple moving average is $53.62 and its 200 day simple moving average is $55.03. Integra LifeSciences has a 1 year low of $37.90 and a 1 year high of $62.99.

Integra LifeSciences (NASDAQ:IART – Get Rating) last posted its quarterly earnings data on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.74. The firm had revenue of $380.85 million during the quarter, compared to analysts’ expectations of $373.21 million. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the company posted $0.74 EPS. Equities research analysts forecast that Integra LifeSciences will post 3.34 EPS for the current year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,843 shares of Integra LifeSciences stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total transaction of $100,056.47. Following the sale, the executive vice president now directly owns 28,796 shares in the company, valued at approximately $1,563,334.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Michael J. Mcbreen sold 1,843 shares of Integra LifeSciences stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total transaction of $100,056.47. Following the sale, the executive vice president now directly owns 28,796 shares in the company, valued at approximately $1,563,334.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Lisa Evoli sold 3,767 shares of Integra LifeSciences stock in a transaction on Monday, February 27th. The stock was sold at an average price of $57.00, for a total transaction of $214,719.00. Following the sale, the executive vice president now owns 18,605 shares in the company, valued at $1,060,485. The disclosure for this sale can be found here. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Integra LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. South Dakota Investment Council raised its position in Integra LifeSciences by 36.0% during the fourth quarter. South Dakota Investment Council now owns 34,396 shares of the life sciences company’s stock worth $1,929,000 after acquiring an additional 9,100 shares during the last quarter. Teza Capital Management LLC raised its position in Integra LifeSciences by 9.7% during the third quarter. Teza Capital Management LLC now owns 8,114 shares of the life sciences company’s stock worth $344,000 after acquiring an additional 716 shares during the last quarter. Teacher Retirement System of Texas raised its position in Integra LifeSciences by 243.4% during the third quarter. Teacher Retirement System of Texas now owns 40,989 shares of the life sciences company’s stock worth $1,736,000 after acquiring an additional 29,054 shares during the last quarter. NorthCrest Asset Manangement LLC raised its position in Integra LifeSciences by 2.8% during the fourth quarter. NorthCrest Asset Manangement LLC now owns 14,180 shares of the life sciences company’s stock worth $795,000 after acquiring an additional 380 shares during the last quarter. Finally, Retirement Systems of Alabama raised its position in Integra LifeSciences by 1.0% during the third quarter. Retirement Systems of Alabama now owns 95,110 shares of the life sciences company’s stock worth $4,029,000 after acquiring an additional 926 shares during the last quarter. Hedge funds and other institutional investors own 87.60% of the company’s stock.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.